NCT00256828

Brief Summary

The purpose of this study is to compare the antiviral activity of two treatment groups for HIV chronic infection: a QD regimen of didanosine, lamivudine and efavirenz versus a BID regimen of zidovudine, lamivudine and efavirenz. Both will be administered with food in the starting treatment of human immunodeficiency virus infection at Week 48.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
360

participants targeted

Target at P75+ for phase_4 hiv-infections

Timeline
Completed

Started Jun 2004

Geographic Reach
1 country

57 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2004

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

November 21, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 22, 2005

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2006

Completed
Last Updated

October 16, 2007

Status Verified

November 1, 2005

First QC Date

November 21, 2005

Last Update Submit

October 15, 2007

Conditions

Keywords

HIV infectionHighly active antiretroviral therapyTreatment Naive

Outcome Measures

Primary Outcomes (1)

  • Percentage of patients with HIV-RNA levels < 50 c/ml (intent-to-treat [ITT])

Secondary Outcomes (6)

  • Percentage of patients with HIV-RNA level < 400 c/ml

  • Time to therapy failure

  • CD4 cell count increase from Baseline to Week 48 (w48)

  • Quality of life changes

  • Compliance to both treatment regimens

  • +1 more secondary outcomes

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Chronic HIV infection with plasma RNA viral burden of HIV \> 2,000 copies/ml obtained in the month prior to randomization.
  • Ages 18 years or older.
  • Women with childbearing potential should use an effective contraceptive method.
  • The subjects should give their written informed consent.
  • The subjects should provide the baseline laboratory values measured during the 4 weeks prior to the start of the study drugs, specified below:
  • serum creatinine \< 1.5 times the upper normal limit;
  • total amylase \< 1.4 times the upper normal limit;
  • liver enzymes (AST, ALT) \< 4 times the upper normal limit.

You may not qualify if:

  • Previous antiretroviral treatment.
  • Suspected (acute) primary HIV infection starting less than six months before.
  • Patients under methadone program
  • Abuse of alcohol or drugs, sufficient, in the investigator's opinion, to prevent an adequate compliance with the study treatment or that could increase the risk of developing pancreatitis or toxic hepatitis.
  • Pregnancy or nursing.
  • History of bilateral peripheral neuropathy or signs and symptoms of bilateral peripheral neuropathy \> Grade 2 on screening.
  • Inability to tolerate oral drugs.
  • Any other clinical condition or previous therapy that, in the investigator's opinion, leads the patient to be inadequate for the study or unable to comply with the dosage requirements.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (57)

Hospital Universitario de San Juan de Alicante

Alicante, Alicante, 03550, Spain

Location

Hospital General de Área de Elda

Elda, Alicante, 03600, Spain

Location

Hospital de Orihuela-Vega Baja, San Bartolomé-Orihuela

Orihuela, Alicante, 03314, Spain

Location

Hospital Son Dureta

Palma de Mallorca, Balearic Islands, 07014, Spain

Location

Hospital Son Llatzer

Palma de Mallorca, Balearic Islands, 07198, Spain

Location

Hospital del Mar

Barcelona, Barcelona, 08003, Spain

Location

Hospital Santa Creu y Sant Pau

Barcelona, Barcelona, 08025, Spain

Location

Hospital General Vall D'Hebrón

Barcelona, Barcelona, 08035, Spain

Location

Hospital de Mollet

Barcelona, Barcelona, 08100, Spain

Location

Consorcio Sanitario de Mataró

Barcelona, Barcelona, 08304, Spain

Location

Hospital De Vic

Barcelona, Barcelona, 08500, Spain

Location

Hospital General de Granollers

Granollers, Barcelona, 08400, Spain

Location

Hospital de Terrassa

Terrassa, Barcelona, 08227, Spain

Location

Hospital Sant Llorenc de Viladecans

Viladecans, Barcelona, 08840, Spain

Location

Hospital General Yagüe

Burgos, Burgos, 09005, Spain

Location

Hospital General de Jerez de la Frontera11407

Jerez de la Frontera, Cadiz, 11407, Spain

Location

Hospital Universitario Marqués de Valdecilla

Santander, Cantabria, 39008, Spain

Location

Hospital Sierrallana de Torrelavega

Torrelavega, Cantabria, 39300, Spain

Location

Hospital General de Castellón

Castellon, Castellon, 12004, Spain

Location

Hospital Provincial Reina Sofía de Córdoba

Córdoba, Cordoba, 14004, Spain

Location

Hospital Provincial Nuestra Señora de la Montaña-Complejo Hospitalario de Cáceres

Cáceres, Cáceres, 10003, Spain

Location

Hospital Comarcal de la Selva

Blanes, Gerona, 17300, Spain

Location

Hospital de Figueres

Figueras, Gerona, 17600, Spain

Location

Hospital de Palamós

Palamós, Gerona, 17230, Spain

Location

Hospital Clínico Universitario San Cecilio

Granada, Granada, 18012, Spain

Location

Hospital Universitario Virgen de las Nieves

Granada, Granada, 18014, Spain

Location

Hospital Donostia

Donostia / San Sebastian, Guipuzcoa, 20014, Spain

Location

Hospital General San Jorge

Huesca, Huesca, 22004, Spain

Location

Hospital Ciudad de Jaén

Jaén, Jaen, 23007, Spain

Location

Hospital Juan Canalejo

A Coruña, La Coruña, 15006, Spain

Location

Hospital Arquitecto Marcide

Ferrol, La Coruña, 15405, Spain

Location

Hospital Príncipe de Asturias

Alcalá de Henares, Madrid, 28880, Spain

Location

Hospital Severo Ochoa

Leganés, Madrid, 28911, Spain

Location

Hospital de la Princesa

Madrid, Madrid, 28006, Spain

Location

Hospital Gregorio Marañón

Madrid, Madrid, 28007, Spain

Location

Hospital Ramón y Cajal

Madrid, Madrid, 28034, Spain

Location

Fundación Jiménez Díaz

Madrid, Madrid, 28040, Spain

Location

Hospital La Paz

Madrid, Madrid, 28046, Spain

Location

Hospital Carlos Haya

Málaga, Malaga, 29010, Spain

Location

Hospital Virgen de la Victoria

Málaga, Malaga, 29010, Spain

Location

Hospital Comarcal Axarquía de Vélez

Málaga, Malaga, 29740, Spain

Location

Hospital General Universitario de Murcia

Murcia, Murcia, 30003, Spain

Location

Hospital General Universitario Morales Meseguer

Murcia, Murcia, 30008, Spain

Location

Hospital Costa del Sol

Marbella, Málaga, 29600, Spain

Location

Hospital de Covadonga-Central de Asturias

Oviedo, Oviedo, 33006, Spain

Location

Complejo Hospitalario de Pontevedra

Pontevedra, Pontevedra, 36001, Spain

Location

Hospital Meixoeiro

Vigo, Pontevedra, 36200, Spain

Location

Hospital Xeral-Cíes de Vigo

Vigo, Pontevedra, 36204, Spain

Location

Hospital General-Central de Asturias

Oviedo, Principality of Asturias, 33006, Spain

Location

Hospital General de Segovia

Segovia, Segovia, 40002, Spain

Location

Hospital General Universitario Sant Joan de Reus

Reus, Tarragona, 43201, Spain

Location

Hospital La Fe de Valencia

Valencia, Valencia, 46009, Spain

Location

Hospital Doctor Peset

Valencia, Valencia, 46017, Spain

Location

Hospital del Río Hortega

Valladolid, Valladolid, 47010, Spain

Location

Hospital de Basurto

Bilbao, Vizcaya, 48013, Spain

Location

Hospital Virgen de la Concha

Zamora, Zamora, 49021, Spain

Location

Hospital Miguel Servet

Zaragoza, Zaragoza, 50009, Spain

Location

Related Publications (1)

  • Berenguer J, Gonzalez J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Perez-Molina JA, Terron JA, Santamaria JM, Pedrol E; GESIDA 3903 Team. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Clin Infect Dis. 2008 Oct 15;47(8):1083-92. doi: 10.1086/592114.

MeSH Terms

Conditions

HIV Infections

Interventions

DidanosineLamivudineefavirenz

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Intervention Hierarchy (Ancestors)

InosinePurine NucleosidesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsDideoxynucleosidesDeoxyribonucleosidesNucleosidesNucleic Acids, Nucleotides, and NucleosidesRibonucleosidesZalcitabineDeoxycytidineCytidinePyrimidine NucleosidesPyrimidinesHeterocyclic Compounds, 1-Ring

Study Officials

  • Juan Berenguer Berenguer, MD

    Gregorio Marañón Hospital

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 21, 2005

First Posted

November 22, 2005

Study Start

June 1, 2004

Study Completion

November 1, 2006

Last Updated

October 16, 2007

Record last verified: 2005-11

Locations